IL155874A0 - Treatment of anxiety disorders - Google Patents

Treatment of anxiety disorders

Info

Publication number: IL155874A0
Authority: IL; Israel
Prior art keywords: treatment; anxiety disorders; anxiety; disorders
Prior art date: 2000-11-15

Application number

IL15587401A

Other languages

English (en)

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-15

Filing date

2001-11-06

Publication date

2003-12-23

2001-11-06 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-12-23 Publication of IL155874A0 publication Critical patent/IL155874A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

IL15587401A 2000-11-15 2001-11-06 Treatment of anxiety disorders IL155874A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24901000P	2000-11-15	2000-11-15
US26536201P	2001-01-31	2001-01-31
PCT/US2001/027801 WO2002040006A2 (en)	2000-11-15	2001-11-06	Treatment of anxiety disorders

Publications (1)

Publication Number	Publication Date
IL155874A0 true IL155874A0 (en)	2003-12-23

Family

ID=26939750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15587401A IL155874A0 (en)	2000-11-15	2001-11-06	Treatment of anxiety disorders

Country Status (16)

Country	Link
EP (1)	EP1395253A2 (xx)
JP (1)	JP2004529073A (xx)
KR (1)	KR20030051812A (xx)
CN (1)	CN1822825A (xx)
AU (1)	AU2002217757A1 (xx)
BR (1)	BR0115301A (xx)
CA (1)	CA2426069A1 (xx)
CZ (1)	CZ20031339A3 (xx)
EA (1)	EA200300567A1 (xx)
HR (1)	HRP20030384A2 (xx)
IL (1)	IL155874A0 (xx)
MX (1)	MXPA03004190A (xx)
NO (1)	NO20032156L (xx)
PL (1)	PL366119A1 (xx)
SK (1)	SK5422003A3 (xx)
WO (1)	WO2002040006A2 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004525912A (ja) *	2001-03-06	2004-08-26	イーライ・リリー・アンド・カンパニー	モノアミン取込の阻害剤
US20040092519A1 (en) *	2002-08-14	2004-05-13	Fred Hassan	New treatment for hot flashes
GB0309440D0 (en) *	2003-04-25	2003-06-04	Lilly Co Eli	Quinolone derivatives
WO2004103356A2 (en) *	2003-05-15	2004-12-02	Eli Lilly And Company	Treatment of emotional dysregulation
CN1889940A (zh) *	2003-12-12	2007-01-03	伊莱利利公司	热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
US8440724B2 (en)	2008-01-09	2013-05-14	Mayo Foundation For Medical Education And Research	Inhibiting neurotransmitter reuptake
US20120220665A1 (en) *	2009-11-03	2012-08-30	Mayo Foundation For Medical Education And Research	Inhibiting Neurotransmitter Reuptake
WO2011056788A2 (en) *	2009-11-03	2011-05-12	Mayo Foundation For Medical Education And Research	Inhibiting neurotransmitter reuptake
US9944618B2 (en)	2013-03-14	2018-04-17	Mayo Foundation For Medical Education And Research	Inhibiting neurotransmitter reuptake
US11446268B2 (en) *	2019-02-01	2022-09-20	Yamo Pharmaceuticals Llc	Compositions and methods for treating anxiety-related disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2931997A (en) *	1996-05-07	1997-11-26	Merck & Co., Inc.	Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (it) *	1998-04-23	2001-05-04	Pharmacia & Upjohn Spa	Uso di reboxetina per il trattamento di disturbi nervosi
KR100948757B1 (ko) *	1999-07-01	2010-03-23	파마시아 앤드 업존 캄파니 엘엘씨	고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법

2001
- 2001-11-06 AU AU2002217757A patent/AU2002217757A1/en not_active Abandoned
- 2001-11-06 BR BR0115301-3A patent/BR0115301A/pt not_active IP Right Cessation
- 2001-11-06 PL PL01366119A patent/PL366119A1/xx not_active Application Discontinuation
- 2001-11-06 IL IL15587401A patent/IL155874A0/xx unknown
- 2001-11-06 CZ CZ20031339A patent/CZ20031339A3/cs unknown
- 2001-11-06 WO PCT/US2001/027801 patent/WO2002040006A2/en not_active Application Discontinuation
- 2001-11-06 CA CA002426069A patent/CA2426069A1/en not_active Abandoned
- 2001-11-06 EA EA200300567A patent/EA200300567A1/ru unknown
- 2001-11-06 KR KR10-2003-7006523A patent/KR20030051812A/ko not_active Application Discontinuation
- 2001-11-06 MX MXPA03004190A patent/MXPA03004190A/es unknown
- 2001-11-06 JP JP2002542380A patent/JP2004529073A/ja active Pending
- 2001-11-06 CN CNA01818927XA patent/CN1822825A/zh active Pending
- 2001-11-06 SK SK542-2003A patent/SK5422003A3/sk not_active Application Discontinuation
- 2001-11-06 EP EP01996376A patent/EP1395253A2/en not_active Withdrawn
2003
- 2003-05-13 NO NO20032156A patent/NO20032156L/no not_active Application Discontinuation
- 2003-05-14 HR HR20030384A patent/HRP20030384A2/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1395253A2 (en)	2004-03-10
NO20032156D0 (no)	2003-05-13
AU2002217757A1 (en)	2002-05-27
CZ20031339A3 (cs)	2003-10-15
JP2004529073A (ja)	2004-09-24
PL366119A1 (en)	2005-01-24
HRP20030384A2 (en)	2003-08-31
CA2426069A1 (en)	2002-05-23
SK5422003A3 (en)	2003-12-02
WO2002040006A2 (en)	2002-05-23
CN1822825A (zh)	2006-08-23
BR0115301A (pt)	2004-12-14
MXPA03004190A (es)	2003-09-22
EA200300567A1 (ru)	2004-10-28
NO20032156L (no)	2003-05-13
WO2002040006A3 (en)	2003-12-24
KR20030051812A (ko)	2003-06-25

Publication	Publication Date	Title
GB0007193D0 (en)	2000-05-17	Treatment of movrmrnt disorders
IL153425A0 (en)	2003-07-06	Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
IL155589A0 (en)	2003-11-23	Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU9527001A (en)	2002-04-22	Treatment of T cell disorders
AU2002360555A8 (en)	2003-06-23	Treatment of genitourinary tract disorders
IL155874A0 (en)	2003-12-23	Treatment of anxiety disorders
HRP20020729A2 (en)	2004-02-29	Treatment of psoriasis
IL150290A0 (en)	2002-12-01	The use of mirtazapine for the treatment of sleep disorders
HUP0102886A3 (en)	2002-12-28	Treatment of anxiety disorders
SI1468686T1 (sl)	2007-04-30	S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
IL151493A0 (en)	2003-04-10	Use of dermaciclane for the treatment of anxiety and depression
EP1303281A4 (en)	2006-02-15	METHODS OF TREATMENT
GB0017951D0 (en)	2000-09-13	Treatment of movement disorders
GB0010496D0 (en)	2000-06-14	Treatment of conditions of the central nervous system
HUP0301798A3 (en)	2004-03-01	Treatment of eating disorders using carboxyalkylethers
GB0003228D0 (en)	2000-04-05	Treatment of GI disorders
GB0029955D0 (en)	2001-01-24	Treatment of neuropsychiatric disorders
GB0125371D0 (en)	2001-12-12	Treatment of movement disorders
GB0021060D0 (en)	2000-10-11	Treatment of functional gastrointestinal disorders
GB9924942D0 (en)	1999-12-22	Treatment of movement disorders
GB0014904D0 (en)	2000-08-09	Methods of treatment
GB0013928D0 (en)	2000-08-02	Methods of treatment
GB0004998D0 (en)	2000-04-19	The treatment of functional gastrointestinal disorders
GB0024704D0 (en)	2000-11-22	Treatment of hyperproliferative skin disorders
GB0219811D0 (en)	2002-10-02	Treatment of excreta